What it's for (Indications)
- Sevelamer is primarily indicated for the control of serum phosphorus levels in adult and pediatric patients (6-18 years of age) with chronic kidney disease (CKD) who are undergoing dialysis.
- Elevated serum phosphorus, a condition known as hyperphosphatemia, is a common and serious complication of CKD, contributing to secondary hyperparathyroidism, renal osteodystrophy, ectopic calcification, and increased cardiovascular morbidity and mortality.
- Sevelamer carbonate, a specific salt form of sevelamer, is also indicated for the control of serum phosphorus in adult patients with CKD who are not yet on dialysis.
- By effectively binding dietary phosphate in the gastrointestinal tract, sevelamer prevents its systemic absorption, thereby helping to maintain serum phosphorus concentrations within the target range recommended by current clinical guidelines to mitigate the adverse effects of hyperphosphatemia.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosing regimen for sevelamer must be individualized based on the patient's serum phosphorus levels and clinical needs, and it should always be administered with meals. For adult patients not currently on a phosphate binder, an initial dose of 800 mg to 1600 mg, taken three times a day with meals, is typically recommended, dependent on baseline serum phosphorus. For instance, if serum phosphorus is >5.5 mg/dL to ≤7.5 mg/dL, an initial dose of 800 mg three times daily may be appropriate. If serum phosphorus exceeds 7.5 mg/dL, a higher initial dose of 1600 mg three times daily might be considered. Subsequent dose adjustments should occur every 2 to 4 weeks, with increments of 800 mg three times daily, until the desired serum phosphorus level is achieved. The average daily dose observed in clinical trials has ranged from approximately 4.8 grams to 14.4 grams. It is crucial that sevelamer tablets are swallowed whole and not crushed, chewed, or broken to avoid potential gastrointestinal irritation or obstruction. For patients with swallowing difficulties, sevelamer powder for oral suspension, mixed with water, is available and should be consumed within 30 minutes of preparation. |
Safety & Warnings
Common Side Effects
- Common adverse effects associated with sevelamer are predominantly gastrointestinal in nature, reflecting its action within the digestive tract.
- These frequently reported side effects include nausea, vomiting, diarrhea, dyspepsia (indigestion), abdominal pain, constipation, and flatulence.
- While generally mild to moderate, these symptoms can affect patient adherence to therapy.
- More serious, albeit less common, gastrointestinal complications that have been reported include bowel obstruction (ileus), bowel perforation, dysphagia (difficulty swallowing), and fecal impaction, some of which may necessitate hospitalization and surgical intervention.
- Furthermore, sevelamer can influence electrolyte balance; it may lead to a reduction in serum bicarbonate levels, potentially contributing to or exacerbating metabolic acidosis.
- Long-term use of sevelamer can also decrease the absorption of fat-soluble vitamins (A, D, E, K) and folic acid, potentially leading to deficiencies that may require supplementation.
- Rarely, aggressive phosphate binding can result in hypophosphatemia, which would necessitate a dose reduction or temporary discontinuation of the medication.
Serious Warnings
- Black Box Warning: Sevelamer does not carry an FDA-mandated Black Box Warning. However, it is crucial for healthcare professionals and patients to be aware of certain serious potential risks, which warrant diligent monitoring and management: **Serious Warnings: 1. Gastrointestinal Complications:** Despite the absence of a formal boxed warning, there have been significant and potentially life-threatening gastrointestinal adverse events reported with sevelamer use. These include cases of bowel obstruction (ileus), fecal impaction, and, rarely, bowel perforation. Some of these events have necessitated surgical intervention and, in rare instances, have been fatal. Patients with a history of major gastrointestinal surgery, severe gastrointestinal motility disorders (e.g., severe constipation, gastroparesis), dysphagia, or any pre-existing bowel obstruction are at an elevated risk. Any new or worsening symptoms such as severe abdominal pain, persistent nausea, vomiting, or significant changes in bowel habits should prompt immediate medical evaluation. Furthermore, sevelamer tablets must be swallowed whole; crushing, chewing, or breaking them is strongly discouraged due to the risk of esophageal irritation, potential for choking, or lodging within the gastrointestinal tract, which can exacerbate these serious GI issues. **2. Vitamin Deficiencies and Metabolic Acidosis:** Long-term use of sevelamer can lead to a significant reduction in the absorption of fat-soluble vitamins (A, D, E, and K) and folic acid. This can result in clinically relevant deficiencies requiring supplementation. Regular monitoring of these vitamin levels is recommended, particularly in patients on prolonged therapy or those with existing nutritional deficits. Additionally, sevelamer carbonate has been shown to decrease serum bicarbonate levels, which can induce or worsen metabolic acidosis. Close monitoring of serum bicarbonate is essential, especially in patients predisposed to acidosis. These potential complications underscore the necessity for comprehensive patient monitoring and proactive intervention to ensure patient safety and optimize therapeutic outcomes.
- Patients receiving sevelamer should be closely monitored for several significant risks.
- Serious gastrointestinal complications, including dysphagia, ileus, bowel obstruction, and bowel perforation, have been reported.
- These events, some of which were fatal, highlight the importance of careful patient selection and monitoring, especially in individuals with a history of major gastrointestinal surgery, bowel obstruction, or severe GI motility disorders.
- Sevelamer tablets must be swallowed whole; they should not be crushed, chewed, or broken due to the risk of esophageal irritation, choking, and potential exacerbation of gastrointestinal adverse events.
- Sevelamer can significantly reduce the absorption of fat-soluble vitamins (A, D, E, K) and folic acid.
- Therefore, routine monitoring of these vitamin levels and appropriate supplementation are recommended, particularly for patients on long-term therapy or those with pre-existing deficiencies.
- Sevelamer carbonate may also reduce serum bicarbonate concentrations, potentially leading to or worsening metabolic acidosis; close monitoring of serum bicarbonate is advised.
- Due to its phosphate-binding properties, sevelamer has the potential to decrease the bioavailability of concomitantly administered oral medications.
- To minimize this risk, other oral drugs should generally be administered at least one hour before or three hours after sevelamer, or as specifically directed by their respective prescribing information.
How it Works (Mechanism of Action)
Sevelamer is a non-absorbed, calcium-free, and metal-free phosphate-binding polymer. Its primary mechanism of action involves the highly effective binding of dietary phosphate within the gastrointestinal tract. The polymer structure of sevelamer contains multiple amine groups, which become protonated in the acidic environment of the stomach and upper small intestine. These positively charged protonated amine groups then form strong ionic and hydrogen bonds with negatively charged phosphate ions present in ingested food. By sequestering dietary phosphate within the lumen of the gastrointestinal tract, sevelamer prevents its absorption into the systemic circulation. The sevelamer-phosphate complex is then expelled from the body via fecal excretion. This targeted action effectively lowers serum phosphorus concentrations without contributing to calcium or aluminum overload, which are potential concerns with other types of phosphate binders. The degree of phosphate binding is dose-dependent, allowing for flexible titration based on individual patient needs.